Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 20/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 11/20 | 1.00 |
| ▸ | IL17A | Q16552 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18940001 | 1.00 | RORC (1.00) | RORCCYP2D6IL17AKCNH2 | |
| SCHEMBL18939918 | 1.00 | RORC (1.00) | RORCCYP2D6IL17AKCNH2 | |
| SCHEMBL29525641 | 1.00 | RORC (1.00) | RORCCYP2D6IL17AKCNH2 | |
| SCHEMBL24031278 | 0.97 | RORC (0.95) | RORCCYP2D6IL17AKCNH2 | |
| SCHEMBL18939838 | 0.93 | RORC (0.86) | RORCCYP2D6IL17AKCNH2 | |
| SCHEMBL29758688 | 0.92 | RORC (1.00) | RORCCYP2D6IL17AKCNH2 | |
| SCHEMBL18939922 | 0.92 | RORC (1.00) | RORCCYP2D6IL17AKCNH2 | |
| SCHEMBL18961548 | 0.92 | RORC (0.84) | RORCCYP2D6IL17AKCNH2 | |
| SCHEMBL18961492 | 0.92 | RORC (0.84) | RORCCYP2D6IL17AKCNH2 | |
| SCHEMBL18940147 | 0.91 | RORC (1.00) | RORCCYP2D6IL17AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3390396-B1 | ISOINDOLE COMPOUNDS | ASTRAZENECA AB (SE) | 2022-07-06 | — | — | EP | claimed |
| CN-109071516-B | Novel compounds | 阿斯利康(瑞典)有限公司 | 2021-08-31 | — | — | CN | claimed |
| US-10988445-B2 | Compounds | ASTRAZENECA AB (SE) | 2021-04-27 | — | — | US | claimed |
| US-20200181084-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2020-06-11 | — | — | US | claimed |
| US-10526286-B2 | Compounds | ASTRAZENECA AB (SE) | 2020-01-07 | — | — | US | claimed |
| US-20190084934-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-03-21 | — | — | US | claimed |
| US-10011566-B2 | Compounds | ASTRAZENECA AB (SE) | 2018-07-03 | — | — | US | claimed |
| US-20170166527-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2017-06-15 | — | — | US | claimed |
| US-20230192620-A1 | ANILINE COMPOUND USED AS RORy REGULATOR | SHANGHAI LITEDD CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192620-A1 | ANILINE COMPOUND USED AS RORy REGULATOR | SHANGHAI LITEDD CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-11453644-B1 | Compounds | ASTRAZENECA, AB (SE) | 2022-09-27 | — | — | US | disclosed |
| EP-3390396-B1 | ISOINDOLE COMPOUNDS | ASTRAZENECA AB (SE) | 2022-07-06 | — | — | EP | disclosed |
| EP-3390396-B1 | ISOINDOLE COMPOUNDS | ASTRAZENECA AB (SE) | 2022-07-06 | — | — | EP | disclosed |
| US-20220202811-A1 | TREATMENT FOR RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR Ɣ (RORƔ)-DEPENDENT CANCERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-30 | — | — | US | disclosed |
| US-10011566-B2 | Compounds | ASTRAZENECA AB (SE) | 2018-07-03 | — | — | US | disclosed |
| US-10011566-B2 | Compounds | ASTRAZENECA AB (SE) | 2018-07-03 | — | — | US | disclosed |
| WO-2017102784-A9 | ISOINDOLE COMPOUNDS | ASTRAZENECA AB (SE) | 2018-04-05 | — | — | WO | disclosed |
| WO-2017102784-A1 | ISOINDOLE COMPOUNDS | ASTRAZENECA AB (SE) | 2017-06-22 | — | — | WO | disclosed |
| US-20170166527-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2017-06-15 | — | — | US | disclosed |
| US-20170166527-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11453644-B1 | Compounds | RORC, RORB, RORA | RORC 1/4885CYP2D6 362/4885IL17A 13/4885 |
| US-10526286-B2 | Compounds | RORC, RORB, RORA | RORC 1/4885CYP2D6 362/4885IL17A 13/4885 |
| US-10988445-B2 | Compounds | RORC, RORB, RORA | RORC 1/4885CYP2D6 362/4885IL17A 13/4885 |
| US-20230192620-A1 | ANILINE COMPOUND USED AS RORy REGULATOR | RORB, RORA, RORC | RORC 3/4885CYP2D6 404/4885IL17A 332/4885 |
| US-10011566-B2 | Compounds | RORC, RORB, RORA | RORC 1/4885CYP2D6 362/4885IL17A 13/4885 |
| US-20200181084-A1 | NOVEL COMPOUNDS | RORC, RORB, RORA | RORC 1/4885CYP2D6 605/4885IL17A 17/4885 |
| US-20190084934-A1 | NOVEL COMPOUNDS | RORC, RORB, RORA | RORC 1/4885CYP2D6 605/4885IL17A 17/4885 |
| US-20170166527-A1 | Novel Compounds | RORC, RORB, RORA | RORC 1/4885CYP2D6 605/4885IL17A 17/4885 |
| US-20220202811-A1 | TREATMENT FOR RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR Ɣ (RORƔ)-DEPENDENT CANCERS | RORA, RORB, RORC | RORC 3/4885CYP2D6 3300/4885IL17A 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.